Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · AtualizadoEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% chance
$11,314 Vol.
$11,314 Vol.
6 out 2026
13% chance
$11,314 Vol.
$11,314 Vol.
6 out 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado Aberto: May 5, 2026, 8:02 PM ET
Volume
$11,314Data de Término
7 out 2026Mercado Aberto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314Data de Término
7 out 2026Mercado Aberto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron signed a non-exclusive technology evaluation agreement in October 2024 granting limited rights to test SmartDepot, a PLGA-based microsphere platform for sustained-release peptide formulations, on Lilly’s candidates. The pact, initially set for about 14 months, was extended through October 7, 2026, to complete additional in-vivo studies and expand scope to next-generation GLP-1 agents and CNS indications such as Alzheimer’s. No public announcements, regulatory filings, or credible reporting indicate a commercial licensing, technology-transfer, or equivalent binding agreement granting full development or sales rights has been reached. Lilly’s parallel long-acting deals with other firms and focus on internal oral and alternative delivery programs further reduce near-term likelihood of a qualifying commercial commitment before the deadline.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions